For patients with a body mass index (BMI)* of 30+ or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition.

Qsymia, the simply convenient choice for weight loss.

Real Results With Qsymia

See the Proven Weight-Loss Results in Real Patients

Extensively studied and prescribed, FDA-approved Qsymia is the once-daily pill that helps you manage your weight-loss plan and set realistic expectations.1,2

See the average results of 3,754 patients who were participating in the studies at the 12, 28 and 56-week time points. These are important time points to help your healthcare provider evaluate your status and assess your treatment plan.1,2‡

The results presented here are from the combined studies supporting FDA approval of Qsymia. The dosing schedule in those studies differ from the dosing schedule that your physician may recommend. As a result of this dosing differential, your results may vary depending on your weight, BMI, diet, activity level, dose of Qsymia, and other factors.

Qsymia was studied in 2 large trials that involved 3,754 patients whose BMI was 27 kg/m2 or greater. For the subjects in the 2 studies the average baseline weight was 256 lbs and 227 lbs, and the average baseline waist circumference was 47 inches and 45 inches. Patients were randomized to placebo, phentermine 3.75 mg/topiramate 23 mg (starter dose), phentermine 7.5 mg/topiramate 46 mg (recommended dose), or phentermine 15 mg/topiramate 92 mg (top dose). In these trials, it was recommended that patients eat a well-balanced diet and reduce their caloric intake by 500 kcal/day.

The chart presents data for patients who completed treatment at each time point. Some patients left the study or stopped taking Qsymia prior to completing the full 56 weeks. The drop off rate for placebo was 47% (687/1477), recommended dose was 31% (150/488) and top dose was 38% (561/1479). The most common reasons (>2% of patients) were: adverse events, patients lost to follow up, patients who withdrew consent, or lack of efficacy.

Analysis of all patients (including those who dropped off) results in slightly smaller reductions in weight and waist circumference. Weight loss in all patients was 4.7 lbs, 14.1 lbs, and 17.2 lbs with placebo, recommended dose, and top dose, respectively, at 12 weeks; 5.4 lbs, 19.5 lbs, and 24.3 lbs with placebo, recommended dose, and top dose, respectively, at 28 weeks; and 3.8 lbs, 19.5 lbs, and 24.7 lbs with placebo, recommended dose, and top dose, respectively, at 56 weeks. The reduction in waist circumference was 1.1 inches, 2.2 inches, and 2.5 inches with placebo, recommended dose, and top dose, respectively, at 12 weeks; 1.3 inches, 3.2 inches, and 3.7 inches with placebo, recommended dose, and top dose, respectively, at 28 weeks; and 1.2 inches, 3.4 inches, and 4.0 inches with placebo, recommended dose, and top dose, respectively, at 56 weeks.1,2

See what real Qsymia patients had to say about their weight-loss results

For 2,289 patients who used Qsymia for 4 months or longer, the top reason impacting their decision to stay on the medication was:

I was satisfied with the results of using the medication

Of 1,427 Qsymia patients who indicated they were satisfied with their results, they identified the following as most important to them:

71%

Feeling better about my physical appearance

56%

Feeling healthier day-to-day

45%

Improved health

QSYMIA PATIENT SURVEY: Online survey conducted in August 2021. Responses from 3,372 Qsymia patients, 18 years or older. Respondents were not remunerated for participating in the survey.

Qsymia, the simply convenient choice for weight loss.

Lose weight and keep it off with diet, exercise and once-daily Qsymia.1,2
Ask your doctor if prescription Qsymia is right for you.

Qsymia Offers Real Control

Qsymia can help you take control of the hunger and cravings you struggle with.1

LEARN HOW

Multiple Ways to Save on Qsymia

Now it’s easier to get Qsymia, manage your plan and achieve your weight-loss goals!

SEE THE REAL SAVINGS

Important Safety Information

Do not take Qsymia if you are pregnant, planning to become pregnant, or become pregnant during Qsymia treatment; have glaucoma; have thyroid problems (hyperthyroidism); are taking certain medicines called monoamine oxidase inhibitors (MAOIs) or have taken MAOIs in the past 14 days; are allergic to topiramate, sympathomimetic amines such as phentermine, or any of the ingredients in Qsymia. See the end of the Medication Guide for a complete list of ingredients in Qsymia.

VIEW ALL +